Middle East Nuclear Medicine Market (2025 - 2033)

Middle East Nuclear Medicine Market Summary

The Middle East nuclear medicine market size was estimated at USD 316.50 million in 2024 and is projected to reach USD 727.3 million by 2033, growing at a CAGR of 8.62% from 2025 to 2033. The market is driven by increasing healthcare infrastructure investments and the rising demand for advanced diagnostic and therapeutic options.

The industry is witnessing significant growth due to advancements in both diagnostic and therapeutic applications, coupled with strategic government investments in healthcare infrastructure. Nuclear medicine plays a vital role in the region’s healthcare transformation, especially as governments recognize its potential for early disease detection and precision-based treatment. , for example, the UAE is investing heavily in nuclear medicine technologies as part of its Vision 2030 initiative. According to the UAE Ministry of Health and Prevention’s Statistical Annual Report of 2023, the government’s health policy includes expanding nuclear medicine centers and providing state-of-the-art cancer treatment services across the nation. The report also highlights that there is an ongoing emphasis on enhancing diagnostic capabilities with cutting-edge technologies, including PET and SPECT scanners.

A significant driver of this market growth is the increasing prevalence of chronic diseases, particularly cancer and cardiovascular conditions, which are putting pressure on healthcare systems to adopt advanced diagnostic and treatment modalities. A Gulf News article published on August 9, 2024, reported that Saudi Arabia has approximately 22,000 new cancer cases, with Riyadh leading the kingdom in cancer cases. Of these, about 17,941 are Saudi nationals, and 4,215 are non-Saudis. Breast cancer is the most prevalent type, with about 3,500 cases recorded. Other common cancers include colon cancer (2,200 cases), lymphoma (1,400 cases), and thyroid cancer (600 cases). This alarming increase in cancer cases has created a pressing need for more specialized healthcare services, including nuclear medicine for early diagnosis and effective treatment. Techniques such as PET and SPECT are becoming integral to oncology protocols, helping doctors detect and assess cancers at early stages. With this rising demand, Saudi Arabia has begun integrating advanced nuclear medicine technologies in several hospitals, including the King Faisal Specialist Hospital in Riyadh, which has recently upgraded its nuclear imaging services to handle the increasing patient load. For instance, The fifth annual UAE International Nuclear Medicine Conference, held in April 2025, highlighted the country's advancements in nuclear medicine. Experts reported successful treatments of prostate and endocrine tumors using targeted radiotherapy, with a 100% tumor control rate in 15 cases. The conference also noted that the UAE operates 14 specialized nuclear medicine centers across various emirates, supported by the latest devices and technologies, positioning the country as a regional leader in this specialty.

In addition to diagnostic advances, nuclear medicine’s therapeutic applications are expanding rapidly across the region. One notable development is the collaboration between the International Atomic Energy Agency (IAEA) and the UAE, which aims to boost the production of radiopharmaceuticals locally. This collaboration, as outlined in a 2024 IAEA report, is focused on improving the UAE’s capacity to produce radiopharmaceuticals for cancer treatment, which will reduce the country’s reliance on imports, also make critical therapies more accessible to underserved populations. This initiative is part of a broader regional strategy to develop self-sufficiency in radiopharmaceuticals, thus lowering costs and ensuring more consistent availability of treatment.

Furthermore, Jordan has positioned itself as a leader in nuclear research with its Jordan Research and Training Reactor (JRTR), which has been operational since 2016. This reactor plays a crucial role in producing medical isotopes used in diagnostic and therapeutic nuclear medicine. The JRTR not only strengthens Jordan’s domestic capabilities but also positions the country as a key player in the regional nuclear medicine landscape, exporting isotopes to other Middle Eastern countries. This development underscores the growing importance of nuclear medicine in the region and the ongoing efforts to enhance access to advanced healthcare solutions.

Market Concentration & Characteristics

The market is moderately concentrated, with global leaders like GE Healthcare, Siemens Healthineers, and Philips Healthcare providing advanced diagnostic imaging and radiopharmaceutical products. Regional players are also emerging, focusing on localized production to meet the growing demand. A key example of this is Jordan, where in July 2025, the Royal Medical Services (RMS) and the Jordan Atomic Energy Commission (JAEC) renewed their cooperation for supplying radioactive iodine-131 produced at the Jordan Research and Training Reactor (JRTR). This agreement underscores the strategic importance of local isotope production for the region’s healthcare needs. Additionally, in 2023, Saudi Arabia’s Energy Minister announced plans to develop the entire nuclear fuel cycle, including producing nuclear fuel for domestic use, to reduce reliance on foreign sources and enhance self-sufficiency in nuclear medicine applications.

The industry is experiencing moderate to high innovation, with advancements primarily seen in diagnostic imaging and therapeutic radiopharmaceuticals. The development of PET and SPECT imaging technologies has significantly improved diagnostic accuracy, particularly in oncology, cardiology, and neurology. Companies like Siemens Healthineers and GE Healthcare are investing in AI-powered imaging systems that enhance efficiency and precision. Furthermore, there is growing innovation in radiopharmaceuticals, such as targeted therapies that improve the effectiveness of cancer treatments.

Barriers to entry in the industry include high capital investment, regulatory complexities, and limited access to skilled professionals. Establishing nuclear medicine facilities requires substantial financial resources due to the cost of advanced equipment such as PET scanners and the infrastructure needed for handling radioactive materials. Regulatory challenges are another significant barrier, as the region is governed by strict laws regarding the production and handling of radioactive substances. Companies must navigate these regulations to obtain necessary licenses, which can be time-consuming and costly. Additionally, the shortage of qualified nuclear medicine specialists and radiologists further complicates market entry, as training programs and specialized education in the field are still in development across many Middle Eastern countries.

Regulations play a crucial role in shaping the industry. Each country has specific rules surrounding the use of radioactive materials, medical imaging technologies, and radiopharmaceutical production. These regulations are primarily designed to ensure patient safety, environmental protection, and the proper handling of radioactive substances. For instance, in the UAE, the Federal Authority for Nuclear Regulation (FANR) monitors and enforces nuclear safety standards, while Saudi Arabia follows strict protocols set by the Saudi Food and Drug Authority (SFDA) for the approval and use of nuclear medicine products. While these regulations ensure safety and quality, they also pose challenges for market players by requiring substantial compliance efforts and added costs. In some countries, regulatory delays can slow down the adoption of new technologies and treatments, impacting the overall growth of the market.

The industry faces competition from alternative diagnostic and treatment modalities, though nuclear medicine remains a preferred option in many cases. For diagnostic imaging, modalities like CT (computed tomography) and magnetic resonance imaging (MRI) are common substitutes for nuclear medicine, offering non-invasive methods with high accuracy in some applications. In cancer treatment, traditional chemotherapy and radiotherapy also serve as substitutes to nuclear medicine-based therapies, particularly in regions where nuclear medicine is less accessible. However, despite these alternatives, nuclear medicine continues to be valued for its unique ability to provide molecular-level insights and offer targeted treatments, especially in oncology. The ability to detect diseases at earlier stages and treat them more precisely gives nuclear medicine a clear advantage in specific applications, despite the presence of substitutes in the market.

Product Insights

The diagnostics segment held the largest market share of 75.90% in 2024, driven by the increasing need for early disease detection and precise imaging, particularly for oncology, cardiology, and neurology applications. Advancements in imaging technologies such as PET and SPECT are improving diagnostic accuracy and facilitating earlier detection of diseases. In March 2024, the UAE Ministry of Health announced the installation of state-of-the-art PET/CT scanners in major public hospitals to enhance diagnostic capabilities for cancer and heart diseases. Additionally, Saudi Arabia is expanding its nuclear medicine infrastructure; in February 2024, King Saud University Medical City in Riyadh launched a new nuclear medicine department, focusing on advanced diagnostic imaging techniques. These developments illustrate the growing emphasis on nuclear medicine for diagnostics in the region.

The therapeutic segment is experiencing rapid growth, driven by the increasing prevalence of cancers and advancements in targeted therapies. Therapeutic radiopharmaceuticals, such as iodine-131, yttrium-90, and lutetium-177, are gaining prominence for their precision in delivering radiation to tumor cells while minimizing damage to surrounding healthy tissues. In April 2025, SHINE Technologies, a nuclear technology company, announced a distribution partnership with Modawina Medical Company to bring its non-carrier-added lutetium-177 (Ilumira) to patients in the UAE. This collaboration aims to increase access to this important cancer-fighting isotope. This initiative reflects the country's commitment to advancing nuclear medicine capabilities. For instance, the hospital has conducted studies on peptide receptor radionuclide therapy (Lu-177 PRRT) for NETs, highlighting its experience over 15 years in this area. Additionally, KFSHRC has been involved in clinical trials combining everolimus with radiolabeled somatostatin analogues for the treatment of NETs.

Application Insights

The urology segment held the largest share of 19.88% in 2024, primarily driven by the increasing prevalence of prostate cancer and benign prostatic hyperplasia (BPH) in the region. Technologies such as prostate-specific membrane antigen (PSMA) imaging and targeted radiopharmaceutical therapies are gaining traction for their precision in diagnosing and treating urological conditions. In June 2025, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh announced a strategic partnership with Cellenkos Inc., a U.S.-based clinical-stage biotech company, to initiate clinical trials for advanced T regulatory (Treg) cell therapies targeting rare diseases with significant unmet medical needs. This collaboration marks a significant milestone in Saudi Arabia's commitment to advancing nuclear medicine and cell-based therapies in urology and oncology.

The endocrine tumors application segment is experiencing rapid growth, primarily due to advancements in targeted therapies and increasing clinical adoption. Peptide receptor radionuclide therapy (PRRT), particularly using lutetium-177 (^177Lu-DOTATATE), has shown efficacy in treating somatostatin receptor-positive neuroendocrine tumors (NETs).In October 2023, Hamad Medical Corporation (HMC) in Qatar introduced Lutetium-177 DOTATATE therapy for the first time in the country, offering a new treatment avenue for patients with advanced neuroendocrine tumors (NETs). The first patient successfully received treatment at the Nuclear Medicine Department of the National Center for Cancer Care and Research (NCCCR). This development eliminates the need for many patients to travel abroad for treatment.

End Use Insights

The hospitals segment held the largest revenue share of 53.00% in 2024, primarily driven by the central role hospitals play in both diagnostic and therapeutic procedures. Hospitals are equipped with advanced nuclear medicine technologies such as PET/CT and SPECT, which are essential for diagnosing complex conditions like cancer, cardiovascular diseases, and neurological disorders. In 2024, hospitals accounted for the majority of nuclear medicine procedures, reflecting their prominence as primary care centers for these specialized treatments.

The segment is also the fastest-growing end-user category, fueled by increasing healthcare demands and the growing prevalence of chronic diseases. With advancements in radiopharmaceutical therapies and imaging techniques, hospitals are expanding their nuclear medicine departments to offer more precise treatments, particularly in oncology and cardiology. For example, King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh’s Cyclotron & Radiopharmaceuticals Department produces over 35 vital radiopharmaceuticals for diagnostic imaging and targeted therapies, supporting approximately 45 nuclear medicine centers across Saudi Arabia. These developments position hospitals as key drivers of the market’s growth and innovation.

Country Insights

Saudi Arabia Nuclear Medicine Market Trends

Saudi Arabia nuclear medicine market is growing rapidly, driven by significant investments in healthcare infrastructure and the increasing demand for advanced diagnostic and therapeutic technologies. The country is focusing on integrating nuclear medicine, particularly in oncology, cardiology, and neurology, with hospitals increasingly adopting technologies like PET/CT and SPECT to improve disease detection and treatment outcomes. The government’s continuous efforts to modernize healthcare facilities and improve access to these technologies are central to this growth. This expansion is aligned with the Kingdom’s Vision 2030 initiative, which aims to elevate the country's healthcare capabilities.

Additionally, King Abdulaziz Medical City's Molecular Imaging and Nuclear Medicine (MINM) section has been providing diagnostic and therapeutic services utilizing radiopharmaceuticals in King Abdulaziz Medical City and King Abdullah Specialized Children Hospital in Riyadh. The section has expanded from conventional technology to hybrid equipment and advanced molecular tracers, performing approximately 10,000 procedures annually. Additionally, the section offers a two-year fellowship training program accredited by the Saudi Commission for Health Specialties, established in 2016, providing comprehensive training in diagnostic and therapeutic aspects of adult and pediatric nuclear medicine.

UAE Nuclear Medicine Market Trends

The UAE nuclear medicine market is rapidly evolving, driven by the government’s investments in healthcare infrastructure and a focus on integrating advanced medical technologies. The country is prioritizing nuclear medicine applications, especially in oncology, cardiology, and neurology. Hospitals are adopting cutting-edge imaging systems to improve the accuracy of diagnostics and enhance treatment precision. The UAE's healthcare initiatives, including expanding public-private partnerships, aim to increase the availability of nuclear medicine services to meet the growing demand for specialized diagnostic and therapeutic care.

UAE has been making significant strides in the field of nuclear medicine. For instance, in April 2025, SHINE Technologies, a nuclear technology company, announced a distribution partnership with Modawina Medical Company to bring its non-carrier-added lutetium-177 (Ilumira) to patients in the UAE. This collaboration aims to increase access to this important cancer-fighting isotope.

Kuwait Nuclear Medicine Market Trends

Kuwait nuclear medicine market is experiencing gradual growth, influenced by factors such as an increasing prevalence of chronic diseases, a growing elderly population, and government initiatives aimed at enhancing healthcare services. A significant development occurred in December 2023 when the Ministry of Health introduced measures to strengthen the country's nuclear medicine resilience and prevent medicine shortages. These measures include improving drug storage capacities and enhancing monitoring of drug consumption and demand. However, despite these efforts, Kuwait continues to lag behind neighboring markets in the development of its nuclear medicine sector due to challenges such as limited domestic manufacturing capabilities and a high reliance on imported nuclear medicines.

In response to these challenges, the government has been working to diversify the economy and attract foreign direct investment into the nuclear medicine sector. For instance, the Kuwait Direct Investment Promotion Authority (KDIPA) has been facilitating investments in various sectors, including healthcare and nuclear medicine manufacturing. However, as per report published in 2023, Kuwait's nuclear medicine industry remains underdeveloped, with the Kuwait Saudi Nuclear Medicine Industries Company being the sole local manufacturer, offering a limited portfolio of generic painkillers and antibiotics. This situation underscores the need for continued investment and development to reduce dependency on imports and enhance the country's nuclear medicine capabilities.

Qatar Nuclear Medicine Market Trends

Qatar nuclear medicine market is evolving rapidly, supported by the nation’s strategic investments in healthcare infrastructure and medical technology. The country is focused on expanding its healthcare offerings to include advanced diagnostic imaging and therapies, with nuclear medicine playing an increasingly prominent role. With a rising prevalence of cancer and cardiovascular diseases, Qatar’s healthcare system is integrating nuclear medicine technologies, particularly in imaging and targeted therapies, to improve patient outcomes and enhance diagnostic accuracy.

In November 2021, the Minister of Public Health, Dr. Hanan Mohamed Al Kuwari, inaugurated a set of new services in the field of Nuclear Medicine at the Clinical Imaging Department of the National Center for Cancer Care and Research (NCCCR) under Hamad Medical Corporation (HMC). These services included the installation of a second Positron Emission Tomography-Computed Tomography (PET/CT) scanner, a second hybrid imaging SPECT/CT scanner, Positron Emission Mammography imaging, a Radio Pharmacy Laboratory, and a Nuclear Medicine Therapy Unit.

Oman Nuclear Medicine Market Trends

Oman nuclear medicine market is steadily progressing, with significant advancements in diagnostic and therapeutic capabilities. The country’s focus on modernizing healthcare infrastructure and integrating advanced medical technologies has been central to its growth. With a rising prevalence of chronic diseases like cancer, Oman is increasingly turning to nuclear medicine as an essential component of early disease detection and treatment. The Omani government is supporting these efforts by funding initiatives aimed at strengthening healthcare facilities and training specialized professionals.

However, Oman has been making significant strides in the field of nuclear medicine. For instance, in May 2025, the Royal Hospital in Muscat successfully completed an external audit of its nuclear medicine services by the IAEA. This audit, conducted through the IAEA’s QUANUM (Quality Management Audit in Nuclear Medicine Practices) methodology, reviewed all clinical, technical, operational, administrative, and management-related procedures to strengthen the quality of its offerings. The findings from this audit are expected to support the hospital’s quality assurance goals and elevate nuclear medicine practices in Oman to international standards.

Key Middle East Nuclear Medicine Company Insights

Key players operating in the Middle East nuclear medicine market are undertaking various initiatives to strengthen their presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are key in propelling the market growth.

Recent Developments

• In May 2025, the Royal Hospital in Muscat, Oman, completed the International Atomic Energy Agency’s (IAEA) Quality Management Audit in Nuclear Medicine Practices (QUANUM), achieving a score of 92.5%, surpassing the global average of 73.9%.

• In March 2025, King Faisal Specialist Hospital in Riyadh initiated a clinical trial for a novel radiolabeled therapy targeting neuroendocrine tumors, aiming to expand nuclear medicine applications for advanced cancer treatments.

Middle East Nuclear Medicine Market